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Hookworm Infection
to the editor: Hotez et al. (Aug. 19 issue)1 suggest
waiting for socioeconomic reforms to eliminate
hookworm infection, a condition that afflicts 740
million persons. However, chronic anemia is an
enormous handicap and limits the prospects of a
better future. We should remember that the fight
against hookworm infection began before the eco-
nomic development of the southern United States
in a large-scale philanthropic effort supported by
the Rockefeller Foundation. In 1902, Dr. Charles
Stiles stated that the poor whites of the South, long
considered lazy, were simply enervated by hook-
worm infection and that “thymol and Epsom salts
[magnesium sulfate] would make those men use-
ful citizens in a few weeks.”2 In less than three years,
the money ($1 million) used to hire sanitation direc-
tors to educate the public and to introduce dispen-
saries for public health reduced hookworm disease
to a minor infection. More important, the locals set
up mechanisms to perpetuate the work, and the
foundation extended the fight to 52 other countries
around the world. Sub-Saharan Africa might bene-
fit from this experience.
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the authors reply:  Dr. Joven makes the impor-
tant, and often underappreciated, point that waiting
for long-term socioeconomic reforms to control
hookworm infection is not a viable option. It was
partly for this reason that the World Health Organi-
zation implemented its resolution to reduce mor-
bidity from soil-transmitted helminth infections,
including hookworm, through large-scale anthel-
mintic chemotherapy programs. The programs will
be largely school-based in order to target school-
children at risk for infection. For reasons discussed
in our article, we believe that this approach may not,
by itself, control hookworm infection worldwide
and that new and complementary tools will proba-
bly be required, which may include a first-genera-
tion recombinant anthelmintic vaccine.1
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Thiazolidinediones
to the editor: In her otherwise excellent review of
thiazolidinediones, Dr. Yki-Järvinen (Sept. 9 issue)1
states that “the effects of rosiglitazone or pioglit-
azone on the size of LDL [low-density lipoprotein]
particles have not been studied in a double-blind,
placebo-controlled trial.” That is not quite the case.
In a double-blind, randomized trial of pioglitazone
as compared with placebo in nondiabetic patients
with normolipidemia and hypertension, pioglita-
zone increased LDL particle size.2 Furthermore, in
two open-label studies involving patients with type
2 diabetes, the size of LDL particles was increased
by rosiglitazone, as compared with placebo,3 and by
pioglitazone, as compared with gliclazide.4
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